IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics

BMC Musculoskeletal Disorders

Volumn 12, Issue , 2011, Pages

  Motokawa, Satoru ^a   Torigoshi, Takafumi ^a   Maeda, Yumi ^a   Maeda, Kazushige ^a   Jiuchi, Yuka ^a   Yamaguchi, Takayuki ^a   Someya, Shinsuke ^a   Shindo, Hiroyuki ^b   Migita, Kiyoshi ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE FACTOR 4 ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; IMMUNOGLOBULIN G; THROMBOCYTE FACTOR 4;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; JAPANESE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SEROCONVERSION; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; BIOSYNTHESIS; BLOOD; CLASSIFICATION; COMPARATIVE STUDY; IMMUNOLOGY; MIDDLE AGED; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; FEMALE; HEPARIN; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PLATELET FACTOR 4; PROSPECTIVE STUDIES; VENOUS THROMBOSIS;

EID: 78751649594     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-12-22     Document Type: Article

References (23)

1. Anderson FA Jr, Spencer FA: Risk factors for venous thromboembolism. Circulation 2003, 107:I9-16.
2. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB: Prevention of venous thromboembolism. Chest 2001, 119:132S-175S.
3. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:338S-400S.
4. Fuji T, Fujita S, Ochi T: Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. Int Orthop 2008, 32:443-51. (Pubitemid 351904622)
5. Fuji T, Ochi T, Niwa S, Fujita S: Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. J Orthop Sci 2008, 13:442-51.
6. Martel N, Lee J, Wells PS: Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005, 106:2710-5. (Pubitemid 41510744)
7. Aster RH: Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995, 332:1374-6.
8. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-5.
9. Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, Greinacher A, Kelton JG: Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005, 106:3791-6. (Pubitemid 41739014)
10. Chong BH: Heparin-induced thrombocytopenia. J Thromb Haemost 2003, 1:1471-8.
11. Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, Eichler P, Warkentin TE: Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007, 5:1666-73. (Pubitemid 47091409)
12. Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A: Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006, 76:420-6.
13. Pouplard C, Leroux D, Regina S, Rollin J, Gruel Y: Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 2010, 103:145-50.
14. Warkentin TE, Chong BH, Greinacher A: Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998, 79:1-7. (Pubitemid 28037046)
15. Walenga JM, Jeske WP, Prechel MM, Bacher P, Bakhos M: Decreased prevalence of heparin-induced thrombocytopenia with low-molecularweight heparin and related drugs. Semin Thromb Hemost 2004, 30:69-80. (Pubitemid 38453585)
16. Newman PM, Chong BH: Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000, 96:182-7. (Pubitemid 30456469)
17. Francis JL: A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Semin Thromb Hemost 2004, 30:359-68.
18. Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:311S-337S.
19. Ahmad S, Haas S, Hoppensteadt DA, Lietz H, Reid U, Bender N, Messmore HL, Misselwitz F, Bacher P, Gaikwad BS, Jeske WP, Walenga JM, Fareed J: Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Thromb Res 2002, 108:49-55. (Pubitemid 36197662)
20. Warkentin TE, Cook RJ, Marder VJ, Greinacher A: Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of nondrug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost 2010, 8:504-12.
21. Warkentin TE, Maurer BT, Aster RH: Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007, 356:2653-5.
22. Weitz JI: New anticoagulants for treatment of venous thromboembolism. Circulation 2004, 110:I19-26.
23. Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M, Herault JP, Cariou R, Herbert JM: Effect of fondaparinux on platelet activation in the presence of heparindependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005, 105:139-44. (Pubitemid 40053075)